Eribulin exerts its pharmacologic effects by binding to the plus ends of microtubules and suppressing microtubule growth, without affecting microtubule shortening, and by inducing the formation of ...
The pharmaceutical company behind mesylate submitted a new drug application for a ready-to-use 3-month formulation of the drug. Foresee Pharmaceuticals submitted to the FDA a 502(b)(2) new drug ...